Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL849505 | 1.00 | ESR1 (0.32) | ESR1CYP3A4CYP2C9ESR2APLNR | |
| SCHEMBL880083 | 1.00 | ESR1 (0.32) | ESR1CYP3A4CYP2C9ESR2APLNR | |
| SCHEMBL9405330 | 0.75 | ADH1B (0.34) | — | |
| SCHEMBL1815106 | 0.74 | ESR1 (0.31) | ESR1CYP3A4CYP2C9ESR2 | |
| SCHEMBL880089 | 0.74 | PLG (0.50) | CYP2C9 | |
| SCHEMBL850536 | 0.74 | PLG (0.50) | CYP2C9 | |
| SCHEMBL850535 | 0.74 | PLG (0.50) | CYP2C9 | |
| SCHEMBL1316560 | 0.72 | ESR2 (0.46) | ESR1CYP3A4CYP2C9ESR2APLNR | |
| SCHEMBL130642 | 0.72 | ESR2 (0.46) | ESR1CYP3A4CYP2C9ESR2APLNR | |
| SCHEMBL2267415 | 0.72 | ESR2 (0.46) | ESR1CYP3A4CYP2C9ESR2APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-20160016956-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-01-21 | — | — | US | disclosed |
| EP-2433940-B9 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2015-10-28 | — | — | EP | disclosed |
| US-9169254-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-27 | — | — | US | disclosed |
| EP-2433940-B1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2014-09-24 | — | — | EP | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| EP-2433940-A1 | SPIROIMIDAZOLONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | ESR1 2016/4885CYP3A4 169/4885CYP2C9 702/4885 |
| US-20160016956-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | ESR1 2016/4885CYP3A4 169/4885CYP2C9 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.